Novavax' Nuvaxovid COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over
The EUA in Taiwan allows Novavax to begin fulfilling its commitment to the COVAX Facility GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ -- Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization (EUA) for Nuvaxovid (NVX-CoV2373)COVID-19 vaccine in individuals aged 18 years and over. Novavax and Taiwan have executed a supply agreement and the doses for Taiwan would represent the first shipment of N...